Dr Michael J Stonnington, MD, | |
4320 15th St Ste A, Gulfport, MS 39501-2524 | |
(228) 867-5012 | |
(228) 575-1964 |
Full Name | Dr Michael J Stonnington |
---|---|
Gender | Male |
Speciality | Orthopedic Surgery |
Experience | 32 Years |
Location | 4320 15th St Ste A, Gulfport, Mississippi |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1710919964 | NPI | - | NPPES |
0122401 | Medicaid | MS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207XX0801X | Orthopaedic Surgery - Orthopaedic Trauma | 16165 (Mississippi) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Encompass Health Home Health Of Gulf Coast | Gulfport, MS | Home health agency |
Mississippi Homecare Of Picayune | Picayune, MS | Home health agency |
Memorial Hospital At Gulfport | Gulfport, MS | Hospital |
George Regional Health System | Lucedale, MS | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Memorial Hospital At Gulfport | 2466524012 | 376 |
News Archive
VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, today announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody.
Child heart deaths at the Bristol Royal Infirmary have fallen markedly, to below the national average, finds a study in this week's BMJ.
Cancer treatments necessarily target unchecked cell growth, and selectively kill cancer cells while sparing normal cells and avoiding general toxicity in the human body.
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses.
› Verified 7 days ago
Entity Name | Memorial Hospital At Gulfport |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1215546635 PECOS PAC ID: 2466524012 Enrollment ID: O20090515000396 |
News Archive
VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, today announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody.
Child heart deaths at the Bristol Royal Infirmary have fallen markedly, to below the national average, finds a study in this week's BMJ.
Cancer treatments necessarily target unchecked cell growth, and selectively kill cancer cells while sparing normal cells and avoiding general toxicity in the human body.
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Michael J Stonnington, MD, Po Box 1810, Gulfport, MS 39502-1810 Ph: (228) 575-1194 | Dr Michael J Stonnington, MD, 4320 15th St Ste A, Gulfport, MS 39501-2524 Ph: (228) 867-5012 |
News Archive
VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for cancer and autoimmune and inflammatory disorders, today announced an in-licensing agreement with Pfizer Inc. for an anti-CD40 monoclonal antibody.
Child heart deaths at the Bristol Royal Infirmary have fallen markedly, to below the national average, finds a study in this week's BMJ.
Cancer treatments necessarily target unchecked cell growth, and selectively kill cancer cells while sparing normal cells and avoiding general toxicity in the human body.
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has accepted and filed the company's supplemental Biologics License Application for subcutaneous use of Xolair (omalizumab) in people with Chronic Idiopathic Urticaria who remained symptomatic despite treatment with H1-antihistamine therapy at approved doses.
› Verified 7 days ago
Philip D Myers, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 15190 Community Rd Ste 120, Gulfport, MS 39503 Phone: 228-205-6825 Fax: 228-831-8782 | |
Dr. Timothy D Jackson, MD, SA-C Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 4500 13th St, Gulfport, MS 39501 Phone: 228-304-9436 | |
Dr. William Lewis Seidensticker, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 2 Bayou Pl, Gulfport, MS 39503 Phone: 222-889-6708 | |
Dr. Eric Jude Letonoff, DO Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 15190 Community Rd Ste 120, Gulfport, MS 39503 Phone: 228-205-6825 Fax: 228-831-8782 | |
Eric J Graham, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 15476 Dedeaux Rd, Gulfport, MS 39503 Phone: 228-230-2663 Fax: 228-679-3038 | |
Dr. Inez M Kelleher, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1340 Broad Ave, Ste 450, Gulfport, MS 39503 Phone: 228-867-5012 Fax: 228-867-5262 | |
Joseph Tyler Cox, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 15476 Dedeaux Rd, Gulfport, MS 39503 Phone: 228-230-2663 Fax: 228-546-3257 |